^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

RAD51Bme Levels as a Potential Predictive Biomarker for PD-1 Blockade Response in Non-Small Cell Lung Cancer

Published date:
04/08/2020
Excerpt:
Remarkably, combining RAD51Bme+ with PD-L1+ improved the sensitivity of the test (68%) to predict immunotherapy response, maintaining high specificity (85%) and increasing positive predictive value (94%)….PD-L1+ and RAD51Bme+ are promising biomarkers to predict response to PD-1 blockade rather than overall prognostic factors in NSCLC’s patients.